CoChat

Liver Bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis

Open access
Eguchi, Akiko, De Mollerat Du Jeu, Xavier, Johnson, Casey D., Nektaria, Andronikou, Feldstein, Ariel E. · 2016 · Journal of Hepatology
Cited by 58

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Background & Aims Liver fibrosis is the most worrisome feature of Nonalcoholic Steatohepatitis (NASH). Growing evidence supports a link between hepatocyte apoptosis and liver fibrogenesis. Our aim was to determine the therapeutic efficacy and safety of liver Bid, a key pro-apoptotic molecule, suppression using RNA interference (RNAi) for the treatment of fibrosis. Methods First, we optimized the delivery system for Bid siRNA in mice using ten different stealth RNAi siRNAs and two lipid formulations -Invivofectamine2.0 and a newly developed inviofectamine3.0 - that have been designed for high efficacy accumulation in the liver, assessed via real time PCR of Bid mRNA. Next, C57BL/6 mice were placed on a choline-deficient L-amino acid defined (CDAA) diet. After 19 wks of CDAA diet, a time-point that results in severe fibrotic-NASH, mice were injected with the selected Bid siRNA-Invivofectamine3.0 biweekly for three weeks. Additionally hepatocyte-specific Bid-deficient (BidΔhep) mice were placed on CDAA diet for 20 wks. Results A maximum Bid knockdown was achieved at 1.5 mg/kg siRNA with inviofectamine3.0, whereas it was at 7 mg/kg with Invivofectamine2.0. In NASH mice, after 3 wks of treatment, BID protein was reduced to 10% and this was associated with an improvement in liver fibrosis and inflammation associated with a marked reduction in TUNEL-positive cells, caspase 3 activation, and a reduction in mitochondrial BAX and BAK. BidΔhep mice showed similar protection from fibrotic changes. Conclusion Our data demonstrate that liver Bid suppression by RNAi technology, as well as hepatocyte-specific Bid-deficiency, improves liver fibrosis coupled with a reduction of inflammation in experimental NASH. These findings are consistent with existing evidence that hepatocyte apoptosis triggers HSC activation and liver fibrosis and suggest that Bid inhibition may be useful as an antifibrotic NASH therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2015.11.002

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 58

Metadata

Authors
Eguchi, A., De Mollerat Du Jeu, X., Johnson, C. D., Nektaria, A., & Feldstein, A. E.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2016-03
Volume
64
Issue
3
Pages
699-707
ISSN
0168-8278 (ISSN-L)
OpenAlex
W2157548057
Cited by
58
References
5
FWCI
4.36
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.